Diabetes Management: Advancing Metabolic Health Through Science, Scale, and Sustainable Innovation:

At AMOLYT LIFESCIENCES, diabetes management stands as a central pillar of our therapeutic strategy and public health commitment. Diabetes represents one of the most formidable health challenges of our time—progressive, multisystemic, and deeply intertwined with modern lifestyles, genetics, and socio-economic transitions. In India alone, more than 101 million people are currently living with diabetes, a number projected to rise to 150 million by 2030, compounded by an undiagnosed population estimated to exceed 40%. Globally, over 540 million individuals are affected today, with projections reaching 850 million by 2045, underscoring the urgency for scalable, science-led solutions.

We view India not only as a high-burden geography, but as a global innovation crucible—where population scale, diversity, and clinical complexity can generate insights and solutions with worldwide relevance. Our diabetes strategy therefore operates across a seamless continuum: translating India-centric innovation into global best practices, while bringing cutting-edge global science to strengthen indigenous healthcare resilience.

• Epidemiology, Causes, and Risk Factors
• India-Specific Drivers
• India’s diabetes epidemic is shaped by a distinctive convergence of biological, environmental, and lifestyle factors:
• Genetic susceptibility, including polymorphisms such as TCF7L2 and CDKAL1, predisposing individuals to early beta-cell dysfunction
• The characteristic “thin–fat” South Asian phenotype, marked by visceral adiposity and insulin resistance even at lower BMI thresholds
• Rapid urbanization and sedentary lifestyles, coupled with increased consumption of refined carbohydrates and ultra-processed foods
• A rising prevalence of gestational diabetes, affecting nearly one in five pregnancies, perpetuating intergenerational metabolic risk
• Tobacco use, pan masala consumption, micronutrient deficiencies, and declining intake of traditional high-fiber grains such as millets
• Together, these factors have resulted in diabetes affecting approximately 12–13% of Indian adults, often at a younger age and with faster progression to complications.

Global Context

Worldwide, diabetes prevalence—currently affecting 10.5% of adults—is driven by parallel forces: obesity and overweight affecting over one billion people, aging populations, physical inactivity, dietary excesses, and widening socio-economic disparities. Low- and middle-income countries now account for the majority of new cases, positioning diabetes as both a medical and developmental challenge of global consequence.

A Comprehensive, Precision-Led Therapeutic Portfolio

Our response to this challenge is anchored in precision medicine, outcomes-based care, and long-term disease modification. We have built a comprehensive antidiabetic portfolio spanning the full disease continuum—from early insulin resistance to advanced cardio-renal-metabolic complications.

Our solutions include:

• Next-generation incretin-based therapies, including dual and triple agonists, integrated with SGLT2 inhibitors for durable glycemic control and cardiorenal protection
• Ultra-long-acting and glucose-responsive basal insulins, designed to reduce hypoglycemia risk and improve adherence
• Advanced oral and injectable GLP-1–based therapies, aligned with real-world patient preferences
• Emerging approaches focused on beta-cell preservation, gut–pancreas axis modulation, and metabolic inflammation control
• All therapies are developed with a strong emphasis on safety, durability, affordability, and relevance to Indian genetic and lifestyle profiles.
• Our efforts align closely with India’s National Programme for Prevention and Control of Non-Communicable Diseases, Ayushman Bharat, and POSHAN 2.0, while remaining harmonized with global standards from the , , and the , including the Global Diabetes Compact.

Vision and Strategic Imperatives

Our vision is unequivocal: to meaningfully reduce the clinical, economic, and societal burden of diabetes by enabling early diagnosis, personalized therapy, and sustained metabolic control.

To realize this, we are executing a focused set of strategic imperatives:

• Portfolio expansion and innovation, with a strong pipeline of next-generation metabolic therapies
• India-anchored, globally compliant clinical research, capturing genetic and phenotypic diversity while meeting international regulatory standards
• Digital enablement, integrating continuous glucose monitoring, AI-driven decision support, and tele-endocrinology to extend specialist care beyond urban centers
• Complication prevention, targeting diabetic kidney disease, cardiovascular disease, amputations, and vision loss through integrated care pathways
• Demonstrated Impact and Measurable Outcomes

Our strategy is underpinned by consistent execution and measurable results:

• Millions of patients supported annually through modern antidiabetic regimens, achieving sustained reductions in HbA1c and major cardiovascular events
• Expanded access to continuous glucose monitoring and digital care platforms, significantly improving time-in-range and reducing hypoglycemia
• Large-scale tele-endocrinology initiatives that have narrowed urban–rural care gaps and accelerated treatment optimization
• These outcomes reflect our ability to deliver clinical excellence at population scale.

Addressing Persistent Challenges

Despite progress, formidable challenges remain. High out-of-pocket expenditure, delayed diagnosis, limited access to advanced monitoring tools in rural regions, and uneven insulin availability continue to compromise outcomes in India and other LMICs. Globally, rising youth-onset type 2 diabetes and persistent inequities in insulin access demand coordinated, system-level responses.

We address these challenges through affordability-driven innovation, resilient supply chains, clinician education, digital health integration, and policy engagement—ensuring sustainability alongside scale.

Long-Term Commitment and Future Outlook

Guided by our core values of scientific excellence, patient-centricity, ethical governance, and collaborative partnership, we are making sustained long-term investments in diabetes research, manufacturing, and access. Through alliances with national institutions, global diabetes organizations, technology partners, and healthcare providers, we continue to strengthen pharmacovigilance, accelerate translational research, and expand integrated diabetes care.

Our ambition is bold yet grounded: to improve metabolic health outcomes for over a billion individuals by 2035, significantly reduce diabetes-related disability and mortality, and establish India as a global fulcrum of diabetes innovation.

Because transforming diabetes care is not only about controlling blood sugar—it is about preserving lives, livelihoods, and the future of global health.